PharmTech Drug Digest 11.20
|Articles|October 3, 2013

Inhalation Drug Delivery, a podcast sponsored by 3M

The practice of using inhaled substances to treat medical conditions has been around for millennia. It?s only in the last hundred years, though, that advancements in technology have allowed inhalation drug delivery systems to become an important delivery method for pharmaceuticals used by millions of patients worldwide. In this episode, Richard Beesley from 3M Drug Delivery Systems gives us an overview of the factors that have shaped inhalation drug delivery and considers how we may best equip ourselves to manage change in the future.


The practice of using inhaled substances to treat medical conditions has been around for millennia. Only in the last hundred years, though, have advancements in technology have allowed inhalation drug delivery systems to become an important delivery method for pharmaceuticals used by millions of patients worldwide. In this interview, Richard Beesley from 3M Drug Delivery Systems provides an overview of the factors that have shaped inhalation drug delivery and considers how we may best equip ourselves to manage change in the future.

Find out about 3M’s Inhalation drug delivery technologies>>

 

Learn more about 3M’s manufacturing capabilities>>

 

Contact a 3M representative>>

 

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.